Drug intelligence / Profile preview

carboplatin + gemcitabine + trilaciclib

Development stage: Unknown
Lead developer: G1 Therapeutics
Modality: Small Molecules
Administration: Intravenous

Overview

A combination therapy consisting of carboplatin, gemcitabine, and trilaciclib. Trilaciclib is an intravenous cyclin-dependent kinase 4/6 (CDK4/6) inhibitor that induces transient cell cycle arrest of hematopoietic stem and progenitor cells and immune cells during chemotherapy exposure, protecting them from chemotherapy-induced damage and potentially enhancing immune activity. Carboplatin and gemcitabine are cytotoxic chemotherapy agents. This combination is primarily being investigated for the treatment of metastatic triple-negative breast cancer.

Targets

CDK6 (Cyclin-dependent kinase 6)CDK4 (Cyclin-dependent kinase 4)DNA

Beyond the preview

Go deeper on carboplatin + gemcitabine + trilaciclib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on carboplatin + gemcitabine + trilaciclib.

Explore the full profile